'Relief to poor': MNC patent on costly TB drug rejected, to 'help' generic production

By A Representative
On March 23, 2023, the Indian Patent Office (IPO) rejected pharma company Janssen’s application for an extension of its patent on bedaquiline, a drug used in the treatment of tuberculosis patients. The verdict that came just a day ahead of World Tuberculosis Day was celebrated by health activists and tuberculosis survivors in India.
Janssen, owned by multinational Johnson and Johnson, applied for an extension of their original patent on bedaquiline on the basis of having discovered a new formulation. According to Indian law, in order to be granted a patent extension in such a situation, the manufacturer has to show that the new formulation leads to an enhanced therapeutic effect. Janssen repeatedly failed to prove that in the case of bedaquiline salt formulation.
If the patent on bedaquiline had been extended, public and family budgets would have remained burdened by unjustifiable high costs of the drug. Bedaquiline is an important drug for TB patients on many counts. The older TB drugs include injectables such as kanamycin, which have severe side effects including permanent hearing loss. On the other hand, bedaquiline is an oral drug with much higher safety and efficacy profile.

Bedaquiline was the first new tuberculosis drug in forty years when it was approved by the US Food and Drug Administration in 2012. According to the most recent Global Tuberculosis Report, in 2021, India recorded 119,000 cases of multidrug resistant tuberculosis and over half a million deaths caused by the disease.
Priyam Lizmary Cherian, an intellectual property lawyer who argued the case at the IPO, said that the decision should ease the generic production of bedaquiline, making safe and effective treatment more accessible. “India, being a generic production hub, can count on companies being able to pick up production after the original patent expires in July 2023,” she said.
Widely recognized as a disease of the poor, tuberculosis is generally not a prominent field in Big Pharma research and development, although it affects the lives of hundreds of thousands in the Global South. In 2021, the money invested in this field globally was not even half of what a UN High Level Meeting identified as a target.
---
Source: Peoples Dispatch / Globetrotter News Service

Xi Jinping’s visit to USA: Recognition that China can't be contained?

By Vijay Prashad President Xi Jinping’s forthcoming visit to the United States must be understood as more than an encounter between two heads of state, but it must be seen as an encounter between two possible futures. In one future, the United States imposes a spiral of confrontation against China. Trade disputes harden into economic warfare, then economic warfare intensifies into technological blockades, technological blockades produce military encirclement, and finally military encirclement creates incidents, and incidents the danger of becoming an unimaginable war.

Swaminarayan, untouchability and the 'we are not Hindu' argument

By Rajiv Shah Following my blog on why the Eiffel Tower authorities should take all the blame for giving in to the Swaminarayan sadhus ’ bizarre demand to “invisibilise” women, including its female staff, during their visit to the internationally renowned Paris tourist centre on September 5, an interesting comment by one of the top academics drew my attention to something I vaguely knew about one of India’s most powerful and richest religious sects.

From margins to microphones: The rise of Dalit hip-hop in India

By Tersina Maria Toppo* A protest does not always arrive as a slogan shouted from a street corner. Sometimes, it arrives on a beat. A microphone replaces the megaphone, a music video becomes a public square, and the smartphone becomes the space where a history once pushed to the margins is narrated, debated, and shared.

Counterview

Search This Blog